Sign In
Buy MCRB
$4.83
+0.0500 (+1.05%)
At Close: Jul 31, 2026
Seres Therapeutics (MCRB)'s Technical Outlook is Bright After Key Golden Cross
10:56am, Thursday, 28'th Aug 2025
After reaching an important support level, Seres Therapeutics, Inc. (MCRB) could be a good stock pick from a technical perspective. MCRB recently experienced a "golden cross" event, which saw its 50-d
Seres Therapeutics to Participate in H.C. Wainwright 27th Annual Global Investment Conference
07:00am, Wednesday, 27'th Aug 2025
CAMBRIDGE, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will attend the upcoming H.C. Wai
Seres Therapeutics, Inc. (MCRB) Q2 2025 Earnings Call Transcript
09:47pm, Wednesday, 06'th Aug 2025
Seres Therapeutics, Inc. (NASDAQ:MCRB ) Q2 2025 Earnings Conference Call August 6, 2025 8:30 AM ET Company Participants Carlo Tanzi - Corporate Participant Investor Relations - Corporate Participant D
Seres (MCRB) Q2 Loss Narrows 34%
09:23pm, Wednesday, 06'th Aug 2025
Seres (MCRB) Q2 Loss Narrows 34%
Seres Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates
07:00am, Wednesday, 06'th Aug 2025
Following FDA input, Seres submitted Phase 2 study protocol to FDA for SER-155 for the prevention of bloodstream infections (BSIs) in adults undergoing allogeneic hematopoietic stem cell transplant (a
Seres Therapeutics: Speculative Gem Backed By SER‑155 FDA Breakthrough
02:09pm, Tuesday, 29'th Jul 2025
Seres Therapeutics's VOWST divestiture injected cash, retired debt, and refocused the company as a clinical‑stage microbiome specialist. Their current lead candidate is SER‑155, which seems to red
Seres Therapeutics to Announce Second Quarter 2025 Financial Results and Business Updates on August 6, 2025
07:01am, Tuesday, 22'nd Jul 2025
CAMBRIDGE, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will host a conference call and l
Seres Therapeutics Presents Expanded SER-155 Exploratory Biomarker Data at 2025 ASCO Annual Meeting
07:00am, Tuesday, 27'th May 2025
Results highlight potential role of SER-155 in promoting peripheral T-cell recovery and immune reconstitution to support favorable outcomes post allogeneic hematopoietic stem cell transplant (allo-HSC
Seres Therapeutics (MCRB) Upgraded to Buy: What Does It Mean for the Stock?
02:58pm, Friday, 23'rd May 2025
Seres Therapeutics (MCRB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Wall Street Analysts Believe Seres Therapeutics (MCRB) Could Rally 713.09%: Here's is How to Trade
11:01am, Friday, 16'th May 2025
The mean of analysts' price targets for Seres Therapeutics (MCRB) points to a 713.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement am
Seres Therapeutics, Inc. (MCRB) Q1 2025 Earnings Call Transcript
02:18pm, Wednesday, 07'th May 2025
Seres Therapeutics, Inc. (NASDAQ:MCRB ) Q1 2025 Earnings Call May 7, 2025 8:30 AM ET Company Participants Carlo Tanzi - Investor Relations Eric Shaff - President and Chief Executive Officer Marella Th
Seres Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates
07:00am, Wednesday, 07'th May 2025
In line with recent FDA feedback, Seres expects to submit a Phase 2 study protocol to FDA in the coming weeks for SER-155 for the prevention of bloodstream infections (BSIs) in adults undergoing allog
CAMBRIDGE, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that it will present three related posters at the
Seres Therapeutics to Announce First Quarter 2025 Financial Results and Business Updates on May 7, 2025
07:00am, Wednesday, 23'rd Apr 2025
CAMBRIDGE, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will host a conference call and
Down -48.7% in 4 Weeks, Here's Why Seres Therapeutics (MCRB) Looks Ripe for a Turnaround
10:35am, Thursday, 17'th Apr 2025
Seres Therapeutics (MCRB) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings
